S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
The 3-Stock Retirement Blueprint (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
The 3-Stock Retirement Blueprint (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
The 3-Stock Retirement Blueprint (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
The 3-Stock Retirement Blueprint (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
NASDAQ:CYTR

CytRx - CYTR Stock Forecast, Price & News

$0.10
+0.01 (+11.70%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.09
$0.10
50-Day Range
$0.08
$0.13
52-Week Range
$0.05
$0.86
Volume
56,090 shs
Average Volume
48,810 shs
Market Capitalization
$4.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYTR stock logo

About CytRx (NASDAQ:CYTR) Stock

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytRx and its competitors with MarketBeat's FREE daily newsletter.

CYTR Stock News Headlines

See More Headlines
Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytRx and its competitors with MarketBeat's FREE daily newsletter.

CYTR Company Calendar

Last Earnings
8/11/2022
Today
10/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTR
Employees
3
Year Founded
N/A

Profitability

Net Income
$-13,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.02 per share

Miscellaneous

Free Float
39,912,000
Market Cap
$4.30 million
Optionable
Not Optionable
Beta
2.10

Key Executives

  • Mr. John Y. Caloz (Age 70)
    CFO, Treasurer & Sr. VP
    Comp: $500k
  • Dr. Stephen Snowdy Ph.D. (Age 52)
    Chief Exec. Officer
  • Molly Carey Poarch
    Global & U.S. Head of Corp. Communications
  • Ms. Molly Painter (Age 46)
    Pres of USA and Head of Launch & Commercial Operations
  • Terri Stevens
    Chief Bus. Officer
  • Ms. Cristina Newman
    Corp. Sec.
  • Dr. Felix Kratz Ph.D. (Age 59)
    Sr. VP, Drug Devel.













CYTR Stock - Frequently Asked Questions

How have CYTR shares performed in 2022?

CytRx's stock was trading at $0.49 on January 1st, 2022. Since then, CYTR shares have decreased by 80.5% and is now trading at $0.0955.
View the best growth stocks for 2022 here
.

How were CytRx's earnings last quarter?

CytRx Co. (NASDAQ:CYTR) posted its quarterly earnings results on Thursday, August, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter.

What is CytRx's stock symbol?

CytRx trades on the NASDAQ under the ticker symbol "CYTR."

How do I buy shares of CytRx?

Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytRx's stock price today?

One share of CYTR stock can currently be purchased for approximately $0.10.

How much money does CytRx make?

CytRx (NASDAQ:CYTR) has a market capitalization of $4.30 million.

How can I contact CytRx?

CytRx's mailing address is 11726 San Vicente Blvd Ste 650, Los Angeles, California 90049-5079. The official website for the company is www.cytrx.com. The company can be reached via phone at (310) 826-5648, via email at info@cytrx.com, or via fax at 310-826-6139.

This page (NASDAQ:CYTR) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.